Safety of epicutaneous immunotherapy for the treatment of peanut allergy: A phase 1 study using the Viaskin patch
Authors:
- 1 April 2016
- journal article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 137 (4) , 1258-1261.e10
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- The regulatory T cells induction by epicutaneous immunotherapy is sustained and mediates long‐term protection from eosinophilic disorders in peanut‐sensitized miceClinical & Experimental Allergy, 2014
- State of the art on food allergen immunotherapy: Oral, sublingual, and epicutaneousJournal of Allergy and Clinical Immunology, 2014
- Epicutaneous Immunotherapy (EPIT) Is Safe for the Treatment of Peanut Allergy in Allergic PatientsJournal of Allergy and Clinical Immunology, 2013
- Epicutaneous Immunotherapy Using a New Epicutaneous Delivery System in Mice Sensitized to PeanutsInternational Archives of Allergy and Immunology, 2010
- US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-upJournal of Allergy and Clinical Immunology, 2010
- Cow's milk epicutaneous immunotherapy in children: A pilot trial of safety, acceptability, and impact on allergic reactivityJournal of Allergy and Clinical Immunology, 2010
- Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergyClinical & Experimental Allergy, 2010
- Further fatalities caused by anaphylactic reactions to food, 2001-2006Journal of Allergy and Clinical Immunology, 2007
- The natural progression of peanut allergy: Resolution and the possibility of recurrenceJournal of Allergy and Clinical Immunology, 2003